KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Receivables (2016 - 2025)

Pfizer (PFE) has disclosed Receivables for 17 consecutive years, with $11.9 billion as the latest value for Q4 2025.

  • Quarterly Receivables rose 3.59% to $11.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.9 billion through Dec 2025, up 3.59% year-over-year, with the annual reading at $11.9 billion for FY2025, 3.59% up from the prior year.
  • Receivables for Q4 2025 was $11.9 billion at Pfizer, down from $14.3 billion in the prior quarter.
  • The five-year high for Receivables was $16.2 billion in Q4 2022, with the low at $10.2 billion in Q3 2023.
  • Average Receivables over 5 years is $12.2 billion, with a median of $11.7 billion recorded in 2023.
  • The sharpest move saw Receivables soared 39.98% in 2022, then tumbled 33.68% in 2023.
  • Over 5 years, Receivables stood at $11.5 billion in 2021, then dropped by 5.03% to $11.0 billion in 2022, then rose by 5.61% to $11.6 billion in 2023, then decreased by 0.89% to $11.5 billion in 2024, then rose by 3.59% to $11.9 billion in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $11.9 billion, $14.3 billion, and $12.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.